Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Buy
58
DVAX Quote, Financials, Valuation and Earnings
Last price:
$10.89
Seasonality move
:
10.12%
Day range:
$10.87 - $11.03
52-week range:
$9.20 - $14.63
Dividend yield:
0%
P/E ratio:
54.00x
P/S ratio:
4.55x
P/B ratio:
2.39x
Volume:
1.1M
Avg. volume:
1.7M
1-year change:
-15.12%
Market cap:
$1.3B
Revenue:
$277.2M
EPS (TTM):
-$0.38
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DVAX
Dynavax Technologies Corp.
|
$94M | $0.12 | 11.43% | 73.54% | $19.25 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$277.2M | $0.15 | 12.73% | -82.4% | $29.05 |
|
ADMA
ADMA Biologics, Inc.
|
$130.5M | $0.16 | 18.96% | -57.14% | $27.25 |
|
ALDX
Aldeyra Therapeutics, Inc.
|
-- | -$0.16 | -- | -47.25% | $9.67 |
|
MRK
Merck & Co., Inc.
|
$17B | $2.35 | 5.81% | 38.62% | $106.62 |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$61.5M | -- | 11.45% | -- | $11.75 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DVAX
Dynavax Technologies Corp.
|
$10.89 | $19.25 | $1.3B | 54.00x | $0.00 | 0% | 4.55x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$27.44 | $29.05 | $4.6B | 17.66x | $0.00 | 0% | 4.41x |
|
ADMA
ADMA Biologics, Inc.
|
$19.85 | $27.25 | $4.7B | 23.31x | $0.00 | 0% | 9.99x |
|
ALDX
Aldeyra Therapeutics, Inc.
|
$4.70 | $9.67 | $282.8M | -- | $0.00 | 0% | -- |
|
MRK
Merck & Co., Inc.
|
$99.72 | $106.62 | $247.5B | 13.19x | $0.81 | 3.25% | 3.93x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$5.39 | $11.75 | $318.5M | -- | $0.00 | 0% | 1.49x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DVAX
Dynavax Technologies Corp.
|
35.13% | -0.293 | 24.82% | 6.74x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.330 | 1.52% | 2.70x |
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -2.565 | 2.38% | 3.53x |
|
ALDX
Aldeyra Therapeutics, Inc.
|
23.99% | 1.936 | 4.95% | 2.64x |
|
MRK
Merck & Co., Inc.
|
44.38% | -0.025 | 20.79% | 1.06x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
2.29% | 0.085 | 3.7% | 2.92x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DVAX
Dynavax Technologies Corp.
|
$80.5M | $21.3M | -5.15% | -7.65% | 22.42% | $32.6M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
ALDX
Aldeyra Therapeutics, Inc.
|
-$63.7K | -$8M | -53.75% | -66.61% | -- | -$7M |
|
MRK
Merck & Co., Inc.
|
$13B | $7.5B | 22.23% | 39.63% | 43.43% | $6.8B |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$51.6M | -$31.3M | -16.2% | -16.55% | -55.61% | -$31.8M |
Dynavax Technologies Corp. vs. Competitors
-
Which has Higher Returns DVAX or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of 28.38% compared to Dynavax Technologies Corp.'s net margin of 25.76%. Dynavax Technologies Corp.'s return on equity of -7.65% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital DVAXDynavax Technologies Corp.84.82% $0.21 $823.4M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About DVAX or ACAD?
Dynavax Technologies Corp. has a consensus price target of $19.25, signalling upside risk potential of 76.77%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $29.05 which suggests that it could grow by 5.88%. Given that Dynavax Technologies Corp. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Dynavax Technologies Corp. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DVAXDynavax Technologies Corp.3 0 1 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is DVAX or ACAD More Risky?
Dynavax Technologies Corp. has a beta of 0.886, which suggesting that the stock is 11.435% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.982%.
-
Which is a Better Dividend Stock DVAX or ACAD?
Dynavax Technologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dynavax Technologies Corp. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DVAX or ACAD?
Dynavax Technologies Corp. quarterly revenues are $94.9M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Dynavax Technologies Corp.'s net income of $26.9M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Dynavax Technologies Corp.'s price-to-earnings ratio is 54.00x while ACADIA Pharmaceuticals, Inc.'s PE ratio is 17.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dynavax Technologies Corp. is 4.55x versus 4.41x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DVAXDynavax Technologies Corp.4.55x 54.00x $94.9M $26.9M ACADACADIA Pharmaceuticals, Inc.4.41x 17.66x $278.6M $71.8M
-
Which has Higher Returns DVAX or ADMA?
ADMA Biologics, Inc. has a net margin of 28.38% compared to Dynavax Technologies Corp.'s net margin of 27.14%. Dynavax Technologies Corp.'s return on equity of -7.65% beat ADMA Biologics, Inc.'s return on equity of 58.71%.
Company Gross Margin Earnings Per Share Invested Capital DVAXDynavax Technologies Corp.84.82% $0.21 $823.4M ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M -
What do Analysts Say About DVAX or ADMA?
Dynavax Technologies Corp. has a consensus price target of $19.25, signalling upside risk potential of 76.77%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $27.25 which suggests that it could grow by 37.28%. Given that Dynavax Technologies Corp. has higher upside potential than ADMA Biologics, Inc., analysts believe Dynavax Technologies Corp. is more attractive than ADMA Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DVAXDynavax Technologies Corp.3 0 1 ADMAADMA Biologics, Inc.4 0 0 -
Is DVAX or ADMA More Risky?
Dynavax Technologies Corp. has a beta of 0.886, which suggesting that the stock is 11.435% less volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.433, suggesting its less volatile than the S&P 500 by 56.749%.
-
Which is a Better Dividend Stock DVAX or ADMA?
Dynavax Technologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dynavax Technologies Corp. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DVAX or ADMA?
Dynavax Technologies Corp. quarterly revenues are $94.9M, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. Dynavax Technologies Corp.'s net income of $26.9M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Dynavax Technologies Corp.'s price-to-earnings ratio is 54.00x while ADMA Biologics, Inc.'s PE ratio is 23.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dynavax Technologies Corp. is 4.55x versus 9.99x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DVAXDynavax Technologies Corp.4.55x 54.00x $94.9M $26.9M ADMAADMA Biologics, Inc.9.99x 23.31x $134.2M $36.4M
-
Which has Higher Returns DVAX or ALDX?
Aldeyra Therapeutics, Inc. has a net margin of 28.38% compared to Dynavax Technologies Corp.'s net margin of --. Dynavax Technologies Corp.'s return on equity of -7.65% beat Aldeyra Therapeutics, Inc.'s return on equity of -66.61%.
Company Gross Margin Earnings Per Share Invested Capital DVAXDynavax Technologies Corp.84.82% $0.21 $823.4M ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M -
What do Analysts Say About DVAX or ALDX?
Dynavax Technologies Corp. has a consensus price target of $19.25, signalling upside risk potential of 76.77%. On the other hand Aldeyra Therapeutics, Inc. has an analysts' consensus of $9.67 which suggests that it could grow by 105.67%. Given that Aldeyra Therapeutics, Inc. has higher upside potential than Dynavax Technologies Corp., analysts believe Aldeyra Therapeutics, Inc. is more attractive than Dynavax Technologies Corp..
Company Buy Ratings Hold Ratings Sell Ratings DVAXDynavax Technologies Corp.3 0 1 ALDXAldeyra Therapeutics, Inc.5 0 0 -
Is DVAX or ALDX More Risky?
Dynavax Technologies Corp. has a beta of 0.886, which suggesting that the stock is 11.435% less volatile than S&P 500. In comparison Aldeyra Therapeutics, Inc. has a beta of 0.831, suggesting its less volatile than the S&P 500 by 16.879%.
-
Which is a Better Dividend Stock DVAX or ALDX?
Dynavax Technologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aldeyra Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dynavax Technologies Corp. pays -- of its earnings as a dividend. Aldeyra Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DVAX or ALDX?
Dynavax Technologies Corp. quarterly revenues are $94.9M, which are larger than Aldeyra Therapeutics, Inc. quarterly revenues of --. Dynavax Technologies Corp.'s net income of $26.9M is higher than Aldeyra Therapeutics, Inc.'s net income of -$7.7M. Notably, Dynavax Technologies Corp.'s price-to-earnings ratio is 54.00x while Aldeyra Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dynavax Technologies Corp. is 4.55x versus -- for Aldeyra Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DVAXDynavax Technologies Corp.4.55x 54.00x $94.9M $26.9M ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M
-
Which has Higher Returns DVAX or MRK?
Merck & Co., Inc. has a net margin of 28.38% compared to Dynavax Technologies Corp.'s net margin of 33.68%. Dynavax Technologies Corp.'s return on equity of -7.65% beat Merck & Co., Inc.'s return on equity of 39.63%.
Company Gross Margin Earnings Per Share Invested Capital DVAXDynavax Technologies Corp.84.82% $0.21 $823.4M MRKMerck & Co., Inc.75.59% $2.32 $93.3B -
What do Analysts Say About DVAX or MRK?
Dynavax Technologies Corp. has a consensus price target of $19.25, signalling upside risk potential of 76.77%. On the other hand Merck & Co., Inc. has an analysts' consensus of $106.62 which suggests that it could grow by 6.92%. Given that Dynavax Technologies Corp. has higher upside potential than Merck & Co., Inc., analysts believe Dynavax Technologies Corp. is more attractive than Merck & Co., Inc..
Company Buy Ratings Hold Ratings Sell Ratings DVAXDynavax Technologies Corp.3 0 1 MRKMerck & Co., Inc.14 13 0 -
Is DVAX or MRK More Risky?
Dynavax Technologies Corp. has a beta of 0.886, which suggesting that the stock is 11.435% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.
-
Which is a Better Dividend Stock DVAX or MRK?
Dynavax Technologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.25% to investors and pays a quarterly dividend of $0.81 per share. Dynavax Technologies Corp. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios DVAX or MRK?
Dynavax Technologies Corp. quarterly revenues are $94.9M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Dynavax Technologies Corp.'s net income of $26.9M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Dynavax Technologies Corp.'s price-to-earnings ratio is 54.00x while Merck & Co., Inc.'s PE ratio is 13.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dynavax Technologies Corp. is 4.55x versus 3.93x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DVAXDynavax Technologies Corp.4.55x 54.00x $94.9M $26.9M MRKMerck & Co., Inc.3.93x 13.19x $17.2B $5.8B
-
Which has Higher Returns DVAX or VNDA?
Vanda Pharmaceuticals, Inc. has a net margin of 28.38% compared to Dynavax Technologies Corp.'s net margin of -40.15%. Dynavax Technologies Corp.'s return on equity of -7.65% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.
Company Gross Margin Earnings Per Share Invested Capital DVAXDynavax Technologies Corp.84.82% $0.21 $823.4M VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M -
What do Analysts Say About DVAX or VNDA?
Dynavax Technologies Corp. has a consensus price target of $19.25, signalling upside risk potential of 76.77%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $11.75 which suggests that it could grow by 118%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than Dynavax Technologies Corp., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than Dynavax Technologies Corp..
Company Buy Ratings Hold Ratings Sell Ratings DVAXDynavax Technologies Corp.3 0 1 VNDAVanda Pharmaceuticals, Inc.3 1 0 -
Is DVAX or VNDA More Risky?
Dynavax Technologies Corp. has a beta of 0.886, which suggesting that the stock is 11.435% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.687, suggesting its less volatile than the S&P 500 by 31.308%.
-
Which is a Better Dividend Stock DVAX or VNDA?
Dynavax Technologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dynavax Technologies Corp. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DVAX or VNDA?
Dynavax Technologies Corp. quarterly revenues are $94.9M, which are larger than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. Dynavax Technologies Corp.'s net income of $26.9M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, Dynavax Technologies Corp.'s price-to-earnings ratio is 54.00x while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dynavax Technologies Corp. is 4.55x versus 1.49x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DVAXDynavax Technologies Corp.4.55x 54.00x $94.9M $26.9M VNDAVanda Pharmaceuticals, Inc.1.49x -- $56.3M -$22.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
